SKI

SKI Full Name

v-ski avian sarcoma viral oncogene homolog

SKI Introduction

SKI (v-ski avian sarcoma viral oncogene homolog) is the cellular homolog of the viral v-ski oncogene originally discovered in retroviruses that transform avian fibroblasts. In humans, the SKI gene encodes a 728-amino acid nuclear proto-oncogene protein that acts as a transcriptional co-regulator, interacting with a variety of transcription factors and corepressor complexes to influence gene expression. The SKI protein is predominantly nuclear and exerts much of its function by modulating signal-dependent transcriptional pathways rather than acting as a classical DNA-binding transcription factor itself. One of its best-characterized roles is inhibition of the transforming growth factor-beta (TGF-β) signaling pathway through direct interaction with SMAD proteins, recruitment of corepressor complexes such as N-CoR/SMRT and histone deacetylases, and competition with coactivators, ultimately repressing TGF-β target gene expression. This regulatory role places SKI at a critical junction controlling cell fate decisions across development and in adult tissues.

Figure 1. The nuclear protein SKI acts as a transcriptional co-regulator, competitively blocking the TGF-β signaling pathway by binding to SMAD proteins and recruiting co-repressors such as N-CoR/HDAC, thereby inhibiting the expression of downstream target genes.

Functionally, SKI influences multiple biological processes including cell proliferation, differentiation, apoptosis and motility by its modulation of TGF-β/Smad and other signaling pathways. In embryonic and tissue development contexts, SKI contributes to neural tube closure, skeletal muscle differentiation and myelination, as well as body composition regulation through effects on myogenic and metabolic gene programs. Its activity in muscle cells can promote myogenesis and lean mass accumulation, and opposingly repress adipogenic pathways, suggesting broader roles in metabolism and muscle biology. Beyond TGF-β modulation, SKI also interacts with factors such as PU.1 in hematopoietic cells, where it can alter lineage commitment and differentiation, and with pathways involving retinoic acid and p53 regulation.

Aberrant expression or mutation of SKI is implicated in a spectrum of human diseases. Overexpression of SKI is observed in various malignancies, including myeloid leukemias, melanoma and other solid tumors, where its repression of tumor-suppressive TGF-β signaling and interactions with pathways like MDM2/p53 support oncogenic functions. At the same time, SKI's role in cancer can be context-dependent, sometimes exhibiting complex effects on tumor growth versus metastasis. Germline mutations in SKI underlie Shprintzen-Goldberg syndrome, a multisystem developmental disorder characterized by craniofacial, skeletal and cognitive abnormalities, presumably through dysregulated TGF-β signaling during development. Additionally, SKI overexpression in hematopoietic stem cells can contribute to myeloproliferative disease, and its dysregulation impacts differentiation and function across other cell types.

Alternate Names for SKI

SKI; v-ski avian sarcoma viral oncogene homolog; SGS; SKV; ski oncogene; ski oncoprotein; proto-oncogene c-Ski;

• 1. Jiang H, et al.; Next generation sequencing analysis of miRNAs: MiR-127-3p inhibits glioblastoma proliferation and activates TGF-β signaling by targeting SKI. OMICS. 2014, 18(3):196-206.